Sign Up
OverviewAPI
The global axial spondyloarthritis (axSpA) market is projected to grow from $5.07 billion in 2022 to $5.54 billion in 2023, reaching $7.55 billion in 2027 with an 8.1% CAGR. The increasing prevalence of spondyloarthritis is driving market growth, with product innovations and major companies like UCB SA developing new drugs. North America currently dominates the market, while the Asia-Pacific region is expected to experience rapid growth. The Russia-Ukraine war has had a significant impact on the global economy, leading to inflation and increased interest rates, affecting various markets globally.

Ask a question